Polarean Imaging Plc operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The firm and its subsidiary company, Polarean, Inc., operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The firm has developed the hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW (xenon Xe 129 hyperpolarized). The company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. Its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
Follow-Up Questions
Polarean Imaging PLC (PLLWF)의 PER은 얼마입니까?
Polarean Imaging PLC의 PER은 N/A입니다
Polarean Imaging PLC의 CEO는 누구입니까?
Dr. Christopher Von Jako은 2023부터 회사에 합류한 Polarean Imaging PLC의 Chief Executive Officer입니다.
PLLWF 주식의 가격 성능은 어떻습니까?
PLLWF의 현재 가격은 0이며, 전 거래일에 decreased 0% 하였습니다.
Polarean Imaging PLC의 주요 사업 주제나 업종은 무엇입니까?
Polarean Imaging PLC은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Polarean Imaging PLC의 시가총액은 얼마입니까?
Polarean Imaging PLC의 현재 시가총액은 $0입니다
Polarean Imaging PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Polarean Imaging PLC에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
